<DOC>
	<DOCNO>NCT00491595</DOCNO>
	<brief_summary>The purpose research study examine safety specific soy component , know isoflavones , find effect ( good bad ) component tissue sensitive hormone estrogen healthy , post-menopausal woman . Isoflavones compound occur naturally soybean extract put capsule form add food . The capsule formulation use study consider investigational drug . This research do many scientist believe isoflavones may play role prevention kinds cancer . While isoflavones safely consume food century , need know soy component safe take high dos extract food provide supplement form . We plan test safety effect soy isoflavones know genistein , daidzein glycitein .</brief_summary>
	<brief_title>Phase I Clinical Study Soy Isoflavones Healthy , Post-Menopausal Women</brief_title>
	<detailed_description>This double blind , Phase I , multiple dose clinical trial orally administer soy isoflavones ( PTI G-2535 , 70 % unconjugated isoflavones contain genistein , daidzein , glycitein ) . This preparation refer soy isoflavones study related document accurately reflect study drug ’ content . The multiple dose trial last four month ( 112 day ) include healthy , post-menopausal woman determine FSH level lack spontaneous bleed least one year . After eligibility determine , potential subject ingest soy shake determine producer daidzein metabolite , equol . We expect find approximately 30 % eligible subject equol-producers publish literature . Equol producer define individual plasma level &gt; 20ug/L ; non-equol producer &lt; 10ug/L 37 . Individuals intermediate equol value ( &gt; 10 ug/L &lt; 20 ug/L ) exclude study . Stratified randomization assign subject one two group , aim 30-40 % equol producer group . Group 1 ( 20 subject ) receive dietary supplement contain 600 mg genistein two dose 300 mg ( part soy isoflavones mixture ) per day orally administer 84-day period . Group 2 ( 10 subject ) receive placebo supplement ( excipients active formulation ) , orally administer 84-day period . These woman recruit local population within Research Triangle area . The study conduct UNC Hospital General Clinical Research Center ( GCRC ) .</detailed_description>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<criteria>Performance status 0 , 1 , 2 ECOG scale Acceptable hematopoietic , hepatic , renal function ( WBC≥3500 µL , platelet count ≥ 100,000/ml , serum creatinine &lt; 2.0 mg/dl , serum bilirubin ≤ 2.0 mg/dl , transaminases &lt; two time normal limit ) Postmenopausal status FSH level &gt; 27 mIU/ml , spontaneous bleed &gt; 1 year Normal mammogram within last 13 month Normal Papanicolaou Test within last 13 month Serious intercurrent medical illness history seizure Significant cardiac disease ( New York Heart Association Class III IV ) Abnormalities physical examination screen include significant abnormality heart , lung , liver , spleen , abdominal organ , neurologic abnormality Abnormalities biochemical screen could metabolically significant Individuals intermediate equol value ( &gt; 10 ug/L &lt; 20 ug/L ) soy challenge Use antibiotic within last 3 month Use hormone/estrogen therapy SERMs within last 3 month Abnormal thyroid endocrine function test ; current use thyroid medication BMI 35 History complete hysterectomy oophorectomy High risk breast cancer ( 5year risk &gt; 1.9 % ) base NCI ’ Breast Cancer Risk Assessment Tool A history malignancy active initially diagnose within 2 year curatively treat nonmelanoma carcinoma skin History substance abuse addiction Alcohol intake great 2 drinks/day 14 drinks/week Tobacco use Diets contain estimate intake 20 mg genistein/day 40mg isoflavone/day AND unwilling/unable reduce soy intake level study period Use supplement contain phytoestrogens estrogenic side effect within 1 month study Premenopausal pregnant Inability read comprehend Informed Consent Life expectancy &lt; 6 month History breast cancer Known soy intolerance On chemotherapy within last 2 year Inability obtain endometrial biopsy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Soy isoflavones</keyword>
	<keyword>Genotoxicity</keyword>
	<keyword>Apoptosis</keyword>
	<keyword>Estrogenic effect</keyword>
</DOC>